Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with ...
If we’re hallucinating, we may not be hallucinating exactly the same thing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback